Patent details
301316 Product Name: fidanacogene elaparvovec
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic Information
- Publication number:
- 301316
- Type:
- Certificate
- SPC Type:
- Medical
- Basic Patent Number:
- EP3581650
- Status:
- Application Pending
- Application number:
- 301316
- Procedural language:
- Dutch
- First Applicant Residence Country:
- Netherlands (NL)
Marketing Authorization
- Marketing Authorization Number:
- EU/1/24/1838
- Marketing Authorization Type:
- EEA
- Marketing Authorization Date:
- 26/07/2024
- Marketing Authorization Country:
- European Union (EU)
Dates
- Filing date:
- 22/01/2025
- First Marketing Authorization date:
- 26/07/2024
- Grant date:
- Activation date:
- Lapsed By Non Payment Annual Fee Date:
- Renunciation Date:
- NullificationDate:
- Registration date:
- 22/01/2025
- SPC/SPC Extension Expiration Date:
- Lapsed By Expiration Date:
- Withdrawal date:
- Revocation Date:
- Invalidity Date:
- Withdrawal Market Authorization Date:
- Refusal Date:
Applicant/holder
- From:
- 22/01/2025
- Name:
- uniQure biopharma B.V.
- Address:
- Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands (NL)
Agent
- Name:
- ir. B.Ch. Ledeboer c.s
- From:
- 22/01/2025
- Address:
- V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC
- Journal edition number:
- 04/25
- Publication date:
- 24/01/2025
- Description:
- Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
| Filing date | Document type | Document Description | Number of pages | File Type | ||
|---|---|---|---|---|---|---|
| 23/01/2025 | Outgoing Correspondence | Confirmation receipt request | 2 | /0/4/2/1/8/0801081240/docs/301316_10_640628l174.pdf | ||
| 22/01/2025 | SPC Documents | Summary of the characteristics of the product | 25 | /0/4/2/1/8/0801081240/docs/301316_0_supplprotectioncertificate20250122042544169.pdf | ||
| 22/01/2025 | SPC Documents | Marketing Authorization SPC | 4 | /0/4/2/1/8/0801081240/docs/301316_1_supplprotectioncertificate20250122042544159.pdf | ||
| 22/01/2025 | SPC Documents | Annex SPC | 2 | /0/4/2/1/8/0801081240/docs/301316_2_supplprotectioncertificate20250122042544204.pdf | ||
| 22/01/2025 | SPC Documents | Annex SPC | 24 | /0/4/2/1/8/0801081240/docs/301316_3_supplprotectioncertificate20250122042544189.pdf | ||
| 22/01/2025 | SPC Documents | Summary of the characteristics of the product | 25 | /0/4/2/1/8/0801081240/docs/301316_4_supplprotectioncertificate20250122042544214.pdf | ||
| 22/01/2025 | SPC Documents | Annex SPC | 6 | /0/4/2/1/8/0801081240/docs/301316_5_supplprotectioncertificate20250122042544179.pdf | ||
| 22/01/2025 | Application Form | First filed application form | 3 | /0/4/2/1/8/0801081240/docs/301316_6_applicationform20250122042544126.pdf | ||
| 22/01/2025 | SPC Documents | Accompanying letter SPC | 3 | /0/4/2/1/8/0801081240/docs/301316_7_supplprotectioncertificate20250122042544150.pdf | ||
| 22/01/2025 | SPC Documents | Annex SPC | 29 | /0/4/2/1/8/0801081240/docs/301316_8_supplprotectioncertificate20250122043012469.pdf | ||
| 22/01/2025 | SPC Documents | Annex SPC | 1 | /0/4/2/1/8/0801081240/docs/301316_9_supplprotectioncertificate20250122043012498.pdf |